FHTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Foghorn Therapeutics Inc (FHTX) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown significant revenue growth and improved financial metrics, the technical indicators are mixed, with bearish moving averages and no clear upward momentum. Additionally, there are no significant positive catalysts or recent influential trading activity to suggest immediate upside potential. The lack of recent news and no strong trading signals further support a 'hold' recommendation for now.
The MACD is positive and expanding, suggesting some bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 4.852, with resistance at 5.11 and support at 4.594. Overall, the technical indicators do not suggest a strong buy signal.
Revenue increased significantly by 223.77% YoY in Q4 2025, and the company has a partnership with Eli Lilly for its lead clinical asset. The MACD indicator shows some bullish momentum.
The stock has bearish moving averages, no significant trading trends from hedge funds or insiders, and no recent news or congress trading activity. Additionally, the stock price has been declining in post-market trading.
In Q4 2025, revenue increased by 223.77% YoY to $9.25 million. Net income improved by 11.08% YoY but remains negative at -$21.66 million. EPS also improved by 9.68% YoY to -0.34. Gross margin remained at 100%. While financials show growth, the company is still not profitable.
Jefferies recently lowered the price target from $14 to $12 but maintained a Buy rating. The analyst highlights the potential for significant price movement (80% higher or 40% lower) based on mid-2026 clinical trial data for FHD-909, the company's lead clinical asset.
